Tag Archives: Intercept Pharma

Cantor Fitzgerald Reiterates a Buy Rating on Intercept Pharma (ICPT)

Cantor Fitzgerald analyst Alethia Young reiterated a Buy rating on Intercept Pharma (ICPT – Research Report) today and set a price target of $170. The company’s shares opened today at $104.56. Young observed: “: We reiterate our Overweight rating and

Analyst Explains Why They Upgraded Their Rating on Intercept Pharma (ICPT)

Oppenheimer analyst Jay Olson upgraded Intercept Pharma (ICPT – Research Report) to Buy yesterday and set a price target of $140. The company’s shares closed on Friday at $102.70. Olson said: “We upgrade ICPT to Outperform based on our view

Analysts’ Top Healthcare Picks: Intercept Pharma (ICPT), Adamas Pharmaceuticals (ADMS)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Intercept Pharma (NASDAQ:ICPT), Adamas Pharmaceuticals (NASDAQ:ADMS) and Adverum Biotechnologies (NASDAQ:ADVM) with bullish sentiments. Intercept Pharma (ICPT) Cowen & Co. analyst Ritu Baral

Intercept Pharma (ICPT) Gets a Buy Rating from Cantor Fitzgerald

Cantor Fitzgerald analyst Alethia Young reiterated a Buy rating on Intercept Pharma (NASDAQ: ICPT) today and set a price target of $170. The company’s shares opened today at $96.01. Young said: “: We reiterate our Overweight rating and price target

Oppenheimer Keeps Their Hold Rating on Intercept Pharma (ICPT)

Oppenheimer analyst Jay Olson maintained a Hold rating on Intercept Pharma (NASDAQ: ICPT) today and set a price target of $100. The company’s shares closed on Friday at $111.58. Olson noted: “While we found no major NASH surprises in AASLD

Intercept Pharma (ICPT) Gets a Buy Rating from Wedbush

In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on Intercept Pharma (NASDAQ: ICPT), with a price target of $217. The company’s shares opened today at $104. According to TipRanks.com, Moussatos is a 3-star analyst with